Page 3 - Pharma Sctors

Entod Pharmaceuticals gets DCGI approval for eye drops to treat presbyopia

Entod Pharmaceuticals on Tuesday said it has received approval from the Drug Controller General of India (DCGI) to market eye drops for the treatment of presbyopia. The Mumbai-based drugmaker has received a final approval for PresVu eye drops and plans to introduce it in the domestic market in the first week of October. The approval follows an earlier recommendation by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO). PresVu is the first eye drop in India specifically developed to reduce dependency on reading glasses for individuals affected by presbyopia, a common age-related vision condition that typically impacts those over 40. "This DCGI approval is a major step forward in our mission to transform eye care in India. PresVu is more than just a product; it's a solution that stands to improve the lives of millions by offering them greater visual independence," Entod Pharmaceuticals CEO Nikkhil K Masurkar said. According to industry ...

Akums Drugs scripts a turnaround, reports Rs 60 cr profit in Q1FY25

Akum's revenue from operations in Q1FY25 came in at Rs 1019.1 crore, a rise of 5.08 per cent Y-o-Y

Here's why Abbott India stock price surged 5% on August 8; details here

The uptick in the pharma company's stock price came after it posted a healthy set of numbers in the June quarter of financial year 2025 (Q1FY25).

Pharma firm Rubicon Research files draft papers for Rs 1,085-cr IPO

Pharmaceutical formulation company Rubicon Research Ltd has filed draft papers with capital markets regulator Sebi to garner Rs 1,085 crore through an initial share sale. The company's Initial Public Offering (IPO) is a combination of a fresh issue of equity shares worth Rs 500 crore and an Offer For Sale (OFS) of shares valued at Rs 585 crore by promoter, General Atlantic Singapore RR Pte Limited, according to the Draft Red Herring Prospectus (DRHP) filed on Wednesday. At present, General Atlantic owns over 57 per cent stake in Rubicon Research. The company proposes to utilise proceeds from the fresh issue to the tune of Rs 310 crore for payment of debt. Also, funds will be used for supporting inorganic growth through unidentified acquisitions as well as other strategic initiatives and general corporate purposes. Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of speciality produ

Senores Pharma files IPO with Sebi, aims to raise Rs 500 cr via fresh issue

Senores Pharmaceuticals Ltd has filed preliminary papers with capital markets regulator Sebi to raise funds through an initial public offering (IPO). The Ahmedabad-based company's IPO is a combination of fresh issuance of shares worth Rs 500 crore and an offer for sale (OFS) of up to 27 lakh equity shares by promoters and other selling shareholders, according to the draft red herring prospectus (DRHP). The offer also includes a reservation for a subscription by eligible employees. The pharma company may consider raising up to Rs 100 crore as pre-IPO placement. If such placement is completed, the fresh issue size will be reduced. Proceeds from its fresh issuance will be utilised for setting up a manufacturing facility for the production of sterile injections in its Atlanta facility; funding the working capital requirements of the company and its subsidiaries; supporting inorganic growth through acquisition and other strategic initiatives and payment of debt. Besides, a portion will

Zydus Life stock price jumps 6% on USFDA nod for Valsartan tablets

The shares surged after the pharmaceutical major announced that it has secured final nod from United States Food and Drug Administration (USFDA) for Valsartan tablets.

Q1 results preview: Niche US products, domestic growth may boost pharma biz

Brokerages expect aggregate sales growth of 11 per cent, and 21 per cent earnings growth during this period

Investors lap up shares of Emcure, Bansal Wire; bids cross Rs 1.25 trillion

The demand for both issuances reflects the positive sentiment among investors and could be a harbinger for more initial public offerings (IPOs) in the coming weeks, said industry players

Indian pharma sites outpace global standards in USFDA inspections for 2023

The USFDA categorised 13 per cent (19 out of 145 inspections) of Indian facilities as 'Official Action Indication'(OAI), which is lower than the global average of 15 per cent OAIs

Cipla: Timely new launches, India outperformance key for margin gains

Brokerages maintain add/buy rating on the stock

Piramal Pharma open to partnerships in OTC; eyes further debt reduction

Piramal said that they are focusing on organic growth across all their verticals - OTC business in India, complex hospital generics, and the Contract Development and Manufacturing (CDMO) business

Pharma firms bank on 'mother brands' to bolster new products: Report

A search conducted by Pharmarack showed that brands of any company, labelled under their mother brands, were observed to enjoy greater market share among their peers

Sun Pharma recalls around 55,000 bottles of generic medication in US

Sun Pharma is recalling about 55,000 bottles of a generic medication to treat bowel disease in the American market, according to the US Food & Drug Administration (USFDA). As per the latest Enforcement Report by the US health regulator, New Jersey-based Sun Pharmaceutical Industries Inc, a unit of the Mumbai-headquartered drug major, is recalling 54,960 bottles of Mesalamine extended-release capsules in the American market. Mesalamine delayed-release capsules are indicated for the treatment of mild to moderate ulcerative colitis. The affected lot of capsules have been manufactured by Sun Pharmaceutical Industries at its Mohali-based manufacturing plant and distributed in the US market by Sun Pharmaceutical Industries Inc. As per the USFDA, the company has initiated the Class II recall due to "Failed Dissolution Specifications". The company initiated the Class II recall on February 5 this year. As per the USFDA, a class II recall is initiated in a situation in which the use of, or

Telangana to develop next phase of 'Genome Valley', says CM Revanth Reddy

The Telangana government will be taking up the next phase of 'Genome Valley', the country's first organised cluster for Life Sciences R&D and clean manufacturing activities here involving an investment of Rs 2,000 crore in 300 acres of land, Chief Minister Revanth Reddy said on Tuesday. Speaking at BioAsia 2024, a healthcare and life sciences annual event, Reddy said the government is also planning to develop ten "Pharma Villages" (clusters) in the state which will have investment potential of Rs one lakh crore. "I am announcing here to establish the next phase of Genome Valley in 300 acres of land with Rs 2,000 crore of investment," he added. He further said the Pharma Villages will have the potential to generate five lakh jobs after they are established. Reddy said the government has also identified clusters for Greenfield Integrated Pharma Villages in Vikarabad, Medak and Nalgonda, all three different areas of Telangana for infrastructure and investment. According to him, the .

Greece entry point for Indian firms to tap European market: PM Mitsotakis

Greece and India have a "lot of complementarities" in shipping, pharma and other sectors, Greek Prime Minister Kyriakos Mitsotakis said on Thursday as he emphasised that his country is the natural entry point for Indian companies to tap the European market. Addressing the 'India-Greece Business Forum', organised by FICCI and Enterprise Greece here, he said Greece and India have a "lot of complementarities" in shipping, pharma, such as defence, drones, agriculture, information and communication technology, tourism. He said "we expect to make concrete announcements very soon regarding the signing of the mobility migration agreement, enabling more Indian labour to come to Greece in an organised manner". On a sector-to-sector approach, the prime minister said, "You will realise that there's a lot of complementarities between sectors where Greece has a comparative advantage and where India is also quite strong." "I can see interesting natural synergies emerging in the technology space,"

Glenmark Pharma eyes $80 mn from it's nasal spray Ryaltris sales next year

Glenmark Pharmaceuticals expects its nasal spray Ryaltris to hit about USD 80 million in sales next year, boosting its overall revenue, according to a top company executive. The drug firm has so far commercialised the product in 31 geographies across the globe. Ryaltris is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age. The drug relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes. "Ryaltris is a huge product for us, right? I mean next year, we anticipate sales of close to about USD 80-odd million. So it's a very large product already in a short time," Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said. The company is yet to launch the product in many of the major markets like China and Brazil, he added. Further, Saldana said, "So I think from peak sales, this will be a substantial product for us

Torrent Pharma Q3 results: Profit after tax jumps 52% to Rs 443 cr

Torrent Pharmaceuticals on Friday reported a 52 per cent increase in its consolidated profit after tax to Rs 443 crore for the third quarter ended December 2023. The drug firm had reported a net profit of Rs 292 crore in the October-December period of the last fiscal. Its revenue increased by 10 per cent to Rs 2,732 crore in the third quarter compared to Rs 2,491 crore in the year-ago period, Torrent Pharmaceuticals said in a statement. The company said its domestic business revenues increased 12 per cent year-on-year to Rs 1,415 crore in the October -December quarter this year. Brazil's business grew by 26 per cent to Rs 312 crore, while the US business expanded by 6 per cent to Rs 274 crore in the third quarter. German revenues for the October-December period witnessed a 12 per cent growth to Rs 270 crore in the December 2023 quarter. Shares of the company on Friday ended 0.51 per cent up at Rs 2,524.70 apiece on the BSE.

Sun Pharma Q3 results: Net profit increases 15% at Rs 2,524 crore

Sales in its US formulations business rose nearly 15 per cent to Rs 3,974 crore, while sales from its India formulations rose more than 11 per cent to Rs 3,779 crore

Govt mulls tweaking PLI schemes in textile, food processing, pharma: Report

The government is considering tweaking production linked incentive (PLI) schemes for certain sectors including textiles, food processing, and pharmaceuticals, a senior official said on Tuesday. The official said that a Cabinet note is finalised to seek approval for the changes from the top authorities. The changes would help these sectors attract more players. The scheme was announced in 2021 for 14 sectors, including telecommunication, white goods, textiles, manufacturing of medical devices, automobiles, speciality steel, food products, high-efficiency solar PV modules, advanced chemistry cell battery, drones and pharma with an outlay of Rs 1.97 lakh crore. While certain sectors like electronics are doing well, others are not performing up to the mark. The government has disbursed Rs 4,415 crore under PLI schemes for eight sectors, including electronics and pharma, till October this fiscal. A total of Rs 1,515 crore was disbursed in FY24 till October, while it was Rs 2,900 crore

Pharma lobby bats for drug approvals in India to align with global markets

Launching a new drug in India takes up to four years longer than in markets such as the United States and the European Union, said the pharma lobby